

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM427516

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Icagen, Inc.		05/15/2017	Corporation: DELAWARE
Icagen Corp.		05/15/2017	Corporation: NEVADA
Icagen-T, Inc.		05/15/2017	Corporation: DELAWARE
Caldera Discovery, Inc.		05/15/2017	Corporation: DELAWARE
XRpro Sciences, Inc.		05/15/2017	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	GPB Debt Holdings II, LLC, as agent		
Street Address:	535 West 24th Street, 4th Floor		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10011		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 8			
Property Type	Number	Word Mark	
Serial Number:	87207564	ADVANCING EARLY DRUG DISCOVERY	
Serial Number:	87207560	HIGH THROUGHPUT CHEMISTRY	
Serial Number:	87207565	HTC	
Serial Number:	87008899	ICAGEN	
Serial Number:	85291101	MXRF	
Serial Number:	87207552	T2L	
Serial Number:	87207561	TARGET-TO-LEAD	
Serial Number:	77377389	XRPRO	
CORRESPONDENCE DATA			
Fax Number:	2024083141		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2024083141		
Email:	jean.paterson@cscglobal.com		
Correspondent Name:	Corporation Service Company		
Address Line 1:	1090 Vermont Avenue, NW		
TRADEMARK			

CH \$215.00 87207564

Address Line 4:	Washington, D.C. 20005
ATTORNEY DOCKET NUMBER:	641171
NAME OF SUBMITTER:	Jean Paterson
SIGNATURE:	/jep/
DATE SIGNED:	05/15/2017
Total Attachments: 18 source=5-15-17 lcagen#page1.tif source=5-15-17 lcagen#page2.tif source=5-15-17 lcagen#page3.tif source=5-15-17 lcagen#page4.tif source=5-15-17 lcagen#page5.tif source=5-15-17 lcagen#page6.tif source=5-15-17 lcagen#page7.tif source=5-15-17 lcagen#page8.tif source=5-15-17 lcagen#page9.tif source=5-15-17 lcagen#page10.tif source=5-15-17 lcagen#page11.tif source=5-15-17 lcagen#page12.tif source=5-15-17 lcagen#page13.tif source=5-15-17 lcagen#page14.tif source=5-15-17 lcagen#page15.tif source=5-15-17 lcagen#page16.tif source=5-15-17 lcagen#page17.tif source=5-15-17 lcagen#page18.tif	

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, modified, supplemented, renewed, restated or replaced from time to time, this “**IP Security Agreement**”), dated May 15, 2017, is made by the Persons listed on the signature pages hereof (collectively, the “**Grantors**”) in favor of GPB Debt Holdings II, LLC, in its capacity as collateral agent (the “**Collateral Agent**”) for itself as a Noteholder and any other Noteholders. All capitalized terms not otherwise defined herein (or as indicated herein as being defined in another document, agreement and/or instrument) shall have the meanings respectively ascribed thereto in the Security Agreement (as defined below).

WHEREAS, Icagen, Inc., a Delaware corporation with offices located at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, NC, 27703 (the “**Parent**”), Icagen-T, Inc., a Delaware corporation and a wholly-owned Subsidiary of the Parent with offices located at 2090 E. Innovation Park Drive, Oro Valley, Arizona 85755 (“**ICA-T**”) and GPB Debt Holdings II, LLC, as investor (the “**Buyer**”) are parties to that certain Securities Purchase Agreement, dated May 15, 2017, pursuant to which ICA-T and the Parent shall be required to sell, and the Buyer shall purchase or have the right to purchase, the ICA-T Note (as defined therein) and the Parent Note and Parent Warrant (both terms as defined therein) from ICA-T and the Parent, respectively;

WHEREAS, it is a condition precedent to the purchase of the ICA-T Note and the Parent Note and Parent Warrants under the Securities Purchase Agreement that each Grantor has executed and delivered that certain Security and Pledge Agreement, dated May 15, 2017, made by the Grantors to the Collateral Agent (as amended, modified, supplemented, renewed, restated or replaced from time to time, the “**Security Agreement**”); and

WHEREAS, under the terms of the Security Agreement, the Grantors have granted to the Collateral Agent, for the benefit of the Noteholders, a security interest in, among other property, certain intellectual property and Licenses of the Grantors, and have agreed as a condition thereof to execute this IP Security Agreement for recording with the U.S. Patent and Trademark Office and the United States Copyright Office; and

WHEREAS, the Grantors have determined that the execution, delivery and performance of this IP Security Agreement directly benefits, and is in the best interest of, the Grantors.

NOW, THEREFORE, in consideration of the premises and the agreements herein and for such other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and in order to induce the Buyer to perform under the Securities Purchase Agreement, each Grantor agrees with the Collateral Agent, for the benefit of the Noteholders, as follows

SECTION 1. Grant of Security. Each Grantor hereby grants to the Collateral Agent for the benefit of the Collateral Agent as a Noteholder and any other Noteholders a security interest in all of such Grantor’s right, title and interest in and to the following (the “**Collateral**”):

- (i) the United States Patents and Patent applications set forth in Schedule A hereto;

(ii) the United States Trademarks and service mark registrations and applications set forth in Schedule B hereto (provided that no security interest shall be granted in United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark applications under applicable federal law), together with the goodwill symbolized thereby;

(iii) all United States Copyrights, whether registered or unregistered, now owned or hereafter acquired by such Grantor, including, without limitation, the copyright registrations and applications and exclusive copyright licenses set forth in Schedule C hereto;

(iv) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;

(v) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and

(vi) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Collateral of or arising from any of the foregoing.

SECTION 2. Security for Obligations. The grant of a security interest in, the Collateral under this IP Security Agreement by each Grantor) secures the payment of all Obligations of each Grantor now or hereafter existing under or in respect of the ICA-T Note and the other Transaction Documents, whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, redemption payments, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise.

SECTION 3. Recordation. Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks and any other applicable government officer record this IP Security Agreement.

SECTION 4. Execution in Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

SECTION 5. Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement. Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein.

SECTION 6. Governing Law; Jurisdiction; Jury Trial.

(i) All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.

(ii) Each Grantor hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim, defense or objection that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under Section 9(f) of the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Collateral Agent or the Noteholders from bringing suit or taking other legal action against any Grantor in any other jurisdiction to collect on a Grantor's obligations or to enforce a judgment or other court ruling in favor of the Collateral Agent or a Noteholder.

(iii) WAIVER OF JURY TRIAL, ETC. EACH GRANTOR IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

(iv) Each Grantor irrevocably and unconditionally waives any right it may have to claim or recover in any legal action, suit or proceeding referred to in this Section any special, exemplary, indirect, incidental, punitive or consequential damages.

[The remainder of the page is intentionally left blank]

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

GRANTORS:

ICAGEN, INC.,

a Delaware corporation

By: 

Name: Richard Cunningham

Title: President and CEO

**ICAGEN CORP. (FORMERLY
KNOWN AS XRPRO CORP.,
FORMERLY KNOWN AS CALDERA
PHARMACEUTICALS, INC.),** a Nevada
corporation

By: 

Name: Richard Cunningham

Title: President and CEO

ICAGEN-T INC., a Delaware corporation

By: 

Name: Richard Cunningham

Title: President and CEO

CALDERA DISCOVERY, INC, a
Delaware corporation

By: 

Name: Richard Cunningham

Title: President and CEO

XRPRO SCIENCES, INC., a Delaware
corporation

By: 

Name: Richard Cunningham

Title: President and CEO

[IP Security Agreement Signature Page]

TRADEMARK

REEL: 006058 FRAME: 0286

ACCEPTED BY:

GPB Debt Holdings II, LLC,
as Collateral Agent

By: _____

A handwritten signature in black ink, appearing to read 'David Gentile', is written over a horizontal line. The signature is stylized and cursive.

Name: David Gentile
Title: Manager

Schedule A
Patents, Etc.

Reference	Title	Country	Application No.	Pub. No.	Patent No.	Status
ICA-001	METHOD FOR DETECTING BINDING EVENTS USING MICRO-X-RAY FLUORESCENCE SPECTROMETRY	United States	09/859,701	2003-0027129	7,858,385	Patented
ICA-002EP	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Europe	3748920	1525458	1525458	Patented
ICA-002BE	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Belgium	3748920	1525458	1525458	Patented
ICA-002CH	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Switzerland	3748920	1525458	1525458	Patented
ICA-002DE	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Germany	3748920	1525458	1525458	Patented
ICA-002DK	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Denmark	3748920	1525458	1525458	Patented
ICA-002ES	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Spain	3748920	1525458	1525458	Patented

Reference	Title	Country	Application No.	Pub. No.	Patent No.	Status
ICA-002FI	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Finland	3748920	1525458	1525458	Patente d
ICA-002FR	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	France	3748920	1525458	1525458	Patente d
ICA-002GB	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	United Kingdom	3748920	1525458	1525458	Patente d
ICA-002IT	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Italy	3748920	1525458	1525458	Patente d
ICA-002SE	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Sweden	3748920	1525458	1525458	Patente d
ICA-002NL	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Netherlands	3748920	1525458	1525458	Patente d
ICA-002JP	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Japan	2004-524531	2006-503268	4560403	Patente d
ICA-002SG	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	Singapore	200500360-3	109345	109345	Patente d

Reference	Title	Country	Application No.	Pub. No.	Patent No.	Status
ICA-002C2	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	United States	11/444,660	2007-0003008	7,519,145	Patented
ICA-002C3	FLOW METHOD AND APPARATUS FOR SCREENING CHEMICALS USING MICRO X-RAY FLUORESCENCE	United States	12/396,592	2009-0175410	7,929,662	Patented
ICA-003EP	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	Europe	4755687.3	1644095	1644095	Patented
ICA-003CH	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	Switzerland/ Liechtenstein	4755687.3	1644095	1644095	Patented
ICA-003DE	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	Germany	4755687.3	1644095	1644095	Patented
ICA-003FR	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	France	4755687.3	1644095	1644095	Patented
ICA-003GB	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	United Kingdom	4755687.3	1644095	1644095	Patented
ICA-003IE	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	Ireland	4755687.3	1644095	1644095	Patented
ICA-003NL	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	Netherlands	4755687.3	1644095	1644095	Patented
ICA-003JP	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	Japan	2006-520181	2007527524	4782676	Patented

Reference	Title	Country	Application No.	Pub. No.	Patent No.	Status
ICA-003SG	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	Singapore	2005085584		118682	Patented
ICA-003	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	United States	10/621,825	2005-0011818	6,858,148	Patented
ICA-003C1	METHOD AND APPARATUS FOR DETECTING CHEMICAL BINDING	United States	10/986,519	2005-0095636	7,241,381	Patented
ICA-004	DRUG DEVELOPMENT AND MANUFACTURING	United States	10/880,388	2004-0235059	9,157,875	Patented
ICA-005EP	X-RAY FLUORESCENCE ANALYSIS METHOD	Europe	7874491.9	2084519	2084519	Patented
ICA-005CH	X-RAY FLUORESCENCE ANALYSIS METHOD	Switzerland/ Liechtenstein	07 874 491.9	2084519	2084519	Patented
ICA-005DE	X-RAY FLUORESCENCE ANALYSIS METHOD	Germany	60 2007 024 468.4	2084519	608007024 468.4	Patented
ICA-005DK	X-RAY FLUORESCENCE ANALYSIS METHOD	Denmark	07 874 491.9	2084519	2084519	Patented
ICA-005FR1	X-RAY FLUORESCENCE ANALYSIS METHOD	France	07 874 491.9	2084519	2084519	Patented
ICA-005GB	X-RAY FLUORESCENCE ANALYSIS METHOD	United Kingdom	7874491.9	2084519	2084519	Patented
ICA-005HK	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	Hong Kong (via EP - 005EPDV)	13104259.3	1177280	1177280	Patented
ICA-005IE	X-RAY FLUORESCENCE ANALYSIS METHOD	Ireland	7874491.9	1177280	2084519	Patented

Reference	Title	Country	Application No.	Pub. No.	Patent No.	Status
ICA-005IT	X-RAY FLUORESCENCE ANALYSIS METHOD	Italy	7874491.9	1177280	2084519	Patented
ICA-005NL	X-RAY FLUORESCENCE ANALYSIS METHOD	Netherlands	7874491.9	1177280	2084519	Patented
ICA-005SE	X-RAY FLUORESCENCE ANALYSIS METHOD	Sweden	7874491.9	1177280	2084519	Patented
ICA-005EPDV	X-RAY MICROSCOPE	Europe	12164870.3	2511844	2511844	Patented
ICA-005CHDV	X-RAY MICROSCOPE	Switzerland and Lichtenstein	12164870.3	2511844	2511844	Patented
ICA-005DEDV	X-RAY MICROSCOPE	Germany	12164870.3	2511844	602007042 616.2	Patented
ICA-005FRDV	X-RAY MICROSCOPE	France	12164870.3	2511844	2511844	Patented
ICA-005GBDV	X-RAY MICROSCOPE	United Kingdom	12164870.3	2511844	2511844	Patented
ICA-005HK	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	Hong Kong (via EP - 005EPDV)	2013104259.3	1177280	1177280	Patented
ICA-005IEDV	X-RAY MICROSCOPE	Ireland	12164870.3	2511844	2511844	Patented
ICA-005JP	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	Japan	2009-532446	2010509566	5143841	Patented
ICA-005JPDV2	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	Japan	2014-123249	2014-123249	5913441	Patented
ICA-005C1	ADVANCED DRUG DEVELOPMENT AND MANUFACTURING	United States	14/693,094	2015-0309021	N/A	Pending

Reference	Title	Country	Application No.	Pub. No.	Patent No.	Status
ICA-006EP	WELL PLATE	Europe	8798006.6	2183644	2183644	Patented
ICA-006BE	WELL PLATE	Belgium	8798007.6	2183644	2183644	Patented
ICA-006CH	WELL PLATE	Switzerland	8798008.6	2183644	2183644	Patented
ICA-006DE	WELL PLATE	Germany	8798009.6	2183644	602008044 640.9	Patented
ICA-006DK	WELL PLATE	Denmark	8798010.6	2183644	2183644	Patented
ICA-006ES	WELL PLATE	Spain	8798011.6	2183644	2183644	Patented
ICA-006FI	WELL PLATE	Finland	8798012.6	2183644	2183644	Patented
ICA-006FR	WELL PLATE	France	8798013.6	2183644	2183644	Patented
ICA-006GB	WELL PLATE	United Kingdom	8798014.6	2183644	2183644	Patented
ICA-006IE	WELL PLATE	Ireland	8798015.6	2183644	2183644	Patented
ICA-006IT	WELL PLATE	Italy	8798016.6	2183644	2183644	Patented
ICA-006 NL	WELL PLATE	Netherlands	8798017.6	2183644	2183644	Patented
ICA-006NO	WELL PLATE	Norway	8798018.6	2183644	2183644	Patented
ICA-006SE	WELL PLATE	Sweden	8798019.6	2183644	2183644	Patented
ICA-006JP	WELL PLATE	Japan	2010-521206	2010537171	5628035	Patented
ICA-006JPDV	WELL PLATE	Japan	2013-117600	2013224946	5755682	Patented
ICA-006JPDV2	WELL PLATE	Japan	2014-202871	2015004692	6076308	Patented
ICA-006	WELL PLATE	United States	12/192,762	2009-0046832	8,238,515	Patented
ICA-006C1	WELL PLATE	United States	13/567,613	2013-0034205	8,873,707	Patented
ICA-006C2	WELL PLATE	United States	14/508,322	2015-0023467	9,476,846	Patented

Reference	Title	Country	Application No.	Pub. No.	Patent No.	Status
ICA-006C3	WELL PLATE	United States	15/273,767	2017-0010228	N/A	Pending
ICA-007JP	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	Japan	2010-5272	2010539944	5743135	Patented
ICA-007JPDV1	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	Japan	2014-221166	2015033386	N/A	Pending
ICA-007C1/XR7-US2	METHOD AND APPARATUS FOR MEASURING PROTEIN POST-TRANSLATIONAL MODIFICATION	United States	15/052,914	2016-0201111	N/A	Pending
ICA-008CN	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	China	200980125952.3	102083365	ZL 200980125952.3	Patented
ICA-008CNDV	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	China	201310298029.8	103411988	2077368	Patented
ICA-008CNDV2	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	China	201510083796.6	N/A	N/A	Pending
ICA-008EP	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	Europe	09774467.6	2306897	N/A	Allowed

Reference	Title	Country	Application No.	Pub. No.	Patent No.	Status
ICA-008HK	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS	Hong Kong	11112984.0	1158478	1158478	Patented
ICA-008	METHOD AND APPARATUS FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	United States	12/496,532	2010-0003697	8,431,357	Patented
ICA-008C1	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE USING X-RAY FLUORESCENCE	United States	13/871,697	2013-0236887	9,063,154	Patented
ICA-008C2	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	United States	14/669,923	2015-0198615	9,506,931	Patented
ICA-008C3	METHOD FOR MEASURING ANALYTE TRANSPORT ACROSS BARRIERS USING X-RAY FLUORESCENCE	United States	15/334,854	2017-0045530	N/A	Pending
ICA-009	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	United States	13/317,341	2012-0093286	9,063,066	Patented
ICA-009C1	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	United States	14/715,206	2015-0276631	9,435,756	Patented

Reference	Title	Country	Application No.	Pub. No.	Patent No.	Status
ICA-009C2	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	United States	14/715,218	2015-0276632	9,442,085	Patented
ICA-009C3	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	United States	14/715,233	2015-0260664	9,335,284	Patented
ICA-009C4	METHOD FOR ANALYSIS USING X-RAY FLUORESCENCE	United States	15/227,292	2016-0341678	N/A	Pending
ICA-010PC	METHODS AND APPARATUS FOR MEASURING METALS AND METALLOIDS	International	PCT/US17/28064	N/A	N/A	Pending

Schedule B
Trademarks

Friday, March 17, 2017	Trademark List	Page: 1
------------------------	-----------------------	---------

Trademark	Case Number/Subcase Country Name	Application Number/Date	Publication Number/Date	Registration Number/Date	Status Next Renewal
ADVANCING EARLY DRUG DISCOVERY Resp.Off.: BO	115730.0002.0012 United States of America	87207564 18-Oct-2016			Pending
	<i>Class(es):</i> 42 Int. <i>Client:</i> ICAgen, Inc. <i>Agent Name:</i> Morgan, Lewis & Bockius LLP <i>Owner:</i> ICAgen, Inc.			<i>Attorney(s):</i> RAD JAK <i>Client Ref:</i> <i>Agent Ref:</i>	
HIGH THROUGHPUT CHEMISTRY Resp.Off.: BO	115730.0002.0008 United States of America	87207560 18-Oct-2016			Pending
	<i>Class(es):</i> 42 Int. <i>Client:</i> ICAgen, Inc. <i>Agent Name:</i> Morgan, Lewis & Bockius LLP <i>Owner:</i> ICAgen, Inc.			<i>Attorney(s):</i> RAD JAK <i>Client Ref:</i> <i>Agent Ref:</i>	
HTC Resp.Off.: BO	115730.0002.0009 United States of America	87207565 18-Oct-2016			Pending
	<i>Class(es):</i> 42 Int. <i>Client:</i> ICAgen, Inc. <i>Agent Name:</i> Morgan, Lewis & Bockius LLP <i>Owner:</i> ICAgen, Inc.			<i>Attorney(s):</i> RAD JAK <i>Client Ref:</i> <i>Agent Ref:</i>	

Trademark	Case Number/Subcase Country Name	Application Number/Date	Publication Number/Date	Registration Number/Date	Status Next Renewal
ICAGEN Resp.Off.: BO	115730.0002.0004 United States of America	87008899 21-Apr-2016			Pending
	<i>Class(es):</i> 42 Int. <i>Client:</i> ICAGEN, Inc. <i>Agent Name:</i> Morgan, Lewis & Bockius LLP <i>Owner:</i> ICAGEN, Inc.			<i>Attorney(s):</i> RAD JAK <i>Client Ref:</i> <i>Agent Ref:</i>	
MXRF Resp.Off.: BO	115730.0002.0003 United States of America	85291101 09-Apr-2011	11-Jun-2013	4390286 27-Aug-2013	Registered 27-Aug-2023
	<i>Class(es):</i> <i>Client:</i> ICAGEN, Inc. <i>Agent Name:</i> Morgan, Lewis & Bockius LLP <i>Owner:</i> ICAGEN, Inc.			<i>Attorney(s):</i> RAD JAK <i>Client Ref:</i> <i>Agent Ref:</i>	
T2L Resp.Off.: BO	115730.0002.0011 United States of America	87207552 18-Oct-2016			Pending
	<i>Class(es):</i> 42 Int. <i>Client:</i> ICAGEN, Inc. <i>Agent Name:</i> Morgan, Lewis & Bockius LLP <i>Owner:</i> ICAGEN, Inc.			<i>Attorney(s):</i> RAD JAK <i>Client Ref:</i> <i>Agent Ref:</i>	

Trademark	Case Number/Subcase Country Name	Application Number/Date	Publication Number/Date	Registration Number/Date	Status Next Renewal
TARGET-TO-LEAD Resp.Off.: BO.	115730.0002.0010 United States of America	87207561 18-Oct-2016			Pending
	<i>Class(es):</i> 42 Int. <i>Client:</i> ICAGEN, Inc. <i>Agent Name:</i> Morgan, Lewis & Bockius LLP <i>Owner:</i> ICAGEN, Inc.			<i>Attorney(s):</i> RAD JAK <i>Client Ref:</i> <i>Agent Ref:</i>	
XRPRO Resp.Off.: BO.	115730.0002.0002 United States of America	77377389 22-Jan-2008	15-Jul-2008	3507712 30-Sep-2008	Registered 30-Sep-2018
	<i>Class(es):</i> 09 Int. <i>Client:</i> ICAGEN, Inc. <i>Agent Name:</i> Morgan, Lewis & Bockius LLP <i>Owner:</i> ICAGEN, Inc.			<i>Attorney(s):</i> RAD JAK <i>Client Ref:</i> <i>Agent Ref:</i>	

Schedule C
Copyrights

None.